Charalampopoulos Athanasios, Gibbs J Simon R, Davies Rachel J, Gin-Sing Wendy, Murphy Kevin, Sheares Karen K, Pepke-Zaba Joanna, Jenkins David P, Howard Luke S
National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom;
National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom; National Heart & Lung Institute, Imperial College London, London, United Kingdom;
J Appl Physiol (1985). 2016 Sep 1;121(3):623-8. doi: 10.1152/japplphysiol.00087.2016. Epub 2016 Jul 14.
We tested the hypothesis that patients with chronic thromboembolic pulmonary hypertension (CTEPH) that was deemed to be inoperable were more likely to respond to drugs for treating pulmonary arterial hypertension (PAH) by using cardiopulmonary exercise (CPX) testing than those with CTEPH that was deemed to be operable. We analyzed CPX testing data of all patients with CTEPH who were treated with PAH drugs and had undergone CPX testing before and after treatment at a single pulmonary hypertension center between February 2009 and March 2013. Suitability for pulmonary endarterectomy (PEA) was decided by experts in PEA who were associated with a treatment center. The group with inoperable CTEPH included 16 patients, the operable group included 26 patients. There were no differences in demographics and baseline hemodynamic data between the groups. Unlike patients in the operable group, after drug treatment patients with inoperable CTEPH had a significantly higher peak V̇o2 (P < 0.001), work load (P = 0.002), and oxygen pulse (P < 0.001). In terms of gas exchange, there was an overall net trend toward improved V̇e/V̇co2 in the group with inoperable CTEPH, with an increased PaCO2 (P = 0.01), suggesting reduced hyperventilation. No changes were observed in patients with operable CTEPH. In conclusion, treatment with PAH drug therapy reveals important pathophysiological differences between inoperable and operable CTEPH, with significant pulmonary vascular and cardiac responses in inoperable disease. Drug effects on exercise function observed in inoperable CTEPH cannot be translated to all forms of CTEPH.
我们通过心肺运动(CPX)测试来验证这一假设:被认为无法手术的慢性血栓栓塞性肺动脉高压(CTEPH)患者比被认为可手术的CTEPH患者更有可能对治疗肺动脉高压(PAH)的药物产生反应。我们分析了2009年2月至2013年3月期间在单个肺动脉高压中心接受PAH药物治疗且在治疗前后均接受过CPX测试的所有CTEPH患者的CPX测试数据。肺动脉内膜剥脱术(PEA)的适用性由与治疗中心相关的PEA专家决定。无法手术的CTEPH组包括16例患者,可手术组包括26例患者。两组之间的人口统计学和基线血流动力学数据没有差异。与可手术组的患者不同,药物治疗后,无法手术的CTEPH患者的峰值摄氧量(P < 0.001)、工作量(P = 0.002)和氧脉搏(P < 0.001)显著更高。在气体交换方面,无法手术的CTEPH组的每分钟静息通气量与二氧化碳排出量比值(V̇e/V̇co2)总体呈改善的净趋势,动脉血二氧化碳分压(PaCO2)升高(P = 0.01),提示过度通气减少。可手术的CTEPH患者未观察到变化。总之,PAH药物治疗揭示了无法手术和可手术的CTEPH之间重要的病理生理差异,无法手术的疾病有显著的肺血管和心脏反应。在无法手术的CTEPH中观察到的药物对运动功能的影响不能推广到所有形式的CTEPH。